Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

Brii Biosciences Limited (BRIBF)

0.3042

+0.0042

+(1.40%)

At close: March 31 at 10:46:11 AM EDT

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.

PR Newswire 6 days ago

BRIBF
+1.40%
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024.

PR Newswire 15 days ago

BRIBF
+1.40%
3 Asian Penny Stocks With Market Caps Under US$5B

Amidst global economic uncertainties, Asian markets have been navigating a complex landscape influenced by trade tensions and evolving monetary policies. In this context, investors often look beyond established giants to explore opportunities in smaller or newer companies. Penny stocks, though an older term, continue to represent these promising ventures with potential value. This article will explore three such stocks that offer financial stability and growth potential for those interested...

Simply Wall St. 25 days ago

6963.HK

BRIBF
+1.40%
Brii Biosciences Leads A Trio Of Promising Penny Stocks

Amid recent market fluctuations, driven by tariff uncertainties and mixed economic data, investors are seeking opportunities in various corners of the market. Penny stocks, a term that may seem outdated but remains relevant, represent smaller or less-established companies that can offer significant value. By focusing on those with robust financials and potential for growth, investors can uncover promising opportunities within this niche segment.

Simply Wall St. last month

BRIBF
+1.40%
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study

Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs announced today that it has entered into an agreement with VBI Vaccines, Inc. and certain of its subsidiaries ("VBI") and its creditor K2 VBI Equity Trust, LLC and K2 HealthVentures LLC, acquiring the intellectual property(IP) and other assets relating to BRII-179.

PR Newswire 3 months ago

BRIBF
+1.40%
Top Penny Stocks To Watch In December 2024

Global markets have been on a rollercoaster ride with U.S. stocks experiencing declines amid cautious Fed commentary and political uncertainty, while economic data paints a mixed picture of resilience and concern. Amidst these fluctuations, investors often look for opportunities that can offer growth potential at lower price points. Penny stocks, though an older term, continue to represent such opportunities by highlighting smaller or newer companies that may offer significant upside when...

Simply Wall St. 3 months ago

MARC.XPHS

BRIBF
+1.40%
3315.HK
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from November 15 - 19 in San Diego, CA.

PR Newswire 4 months ago

BRIBF
+1.40%
Top Penny Stocks To Watch In November 2024

Global markets have experienced significant shifts, with U.S. stocks rallying to record highs following a Republican "red sweep" in the recent elections, sparking hopes for growth and tax reforms. Amid these changes, investors are increasingly seeking opportunities in smaller or newer companies often referred to as penny stocks—a term that may sound outdated but remains relevant today. These stocks can offer growth potential at lower price points, especially when they possess strong...

Simply Wall St. 4 months ago

F03.SI

0673.HK

BRIBF
+1.40%
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, presented new data from two Phase 2 studies evaluating BRII-179 either as a combination therapy with BRII-835 (elebsiran) or as an add-on therapy to pegylated interferon-alpha (PEG-IFNα) treatment for chronic hepatitis B virus (HBV) infection at the EASL™ (European Association for the Study of

PR Newswire 9 months ago

BRIBF
+1.40%
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designations for BRII-877 (tobevibart), an investigational broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), a

PR Newswire 10 months ago

BRIBF
+1.40%